Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Intelligence Hub
News
Changes
Search
Log in
Get Started
MIPLYFFA (ARIMOCLOMOL CITRATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
MIPLYFFA
NDA
ARIMOCLOMOL CITRATE | N214927 | ZEVRA DENMARK AS
4 strengths
4 unique patents
2 unique exclusivities
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Price Trends
VA FSS
Medicare D
Approvals
Label
Products
Patent Timeline
4 unique patents, 2 exclusivities by expiration date
All strengths
EQ 47MG BASE
EQ 62MG BASE
EQ 93MG BASE
EQ 124MG BASE
Active (4)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
Today
9289472
Aug. 11, 2029
9884058
Jun. 26, 2029
11045460
Aug. 19, 2029
11707456
Nov. 19, 2041
NCE
Sep. 20, 2029
ODE-496
Sep. 20, 2031
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (4)
Sort:
Name
↑
Applicant
Strength
Approval
#001 — EQ 47MG BASE
RLD
4 patents
2 exclusivities
▴
CAPSULE;ORAL | Approved: Sep 20, 2024
Patents (4)
· 4 use codes
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9289472
Aug 11, 2029
—
—
—
U-4021
USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC)
—
9884058
Jun 26, 2029
—
—
—
U-4021
USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC)
—
11045460
Aug 19, 2029
—
—
—
U-4021
USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC)
—
11707456
Nov 19, 2041
—
Yes
Yes
U-4021
USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC)
—
Exclusivities (2)
Code
Date
Status
NCE
Sep 20, 2029
Active
ODE-496
Sep 20, 2031
Active
#002 — EQ 62MG BASE
RLD
4 patents
2 exclusivities
▾
CAPSULE;ORAL | Approved: Sep 20, 2024
#003 — EQ 93MG BASE
RLD
4 patents
2 exclusivities
▾
CAPSULE;ORAL | Approved: Sep 20, 2024
#004 — EQ 124MG BASE
RLD
4 patents
2 exclusivities
▾
CAPSULE;ORAL | Approved: Sep 20, 2024